Objective-Heparanase is an endoglycosidase that specifically cleaves carbohydrate chains of heparan sulfate. We have recently reported that high fatty acid increased the nuclear content of endothelial heparanase. Here, we examined the mechanism and the consequences behind this nuclear translocation of heparanase. Methods and Results-Bovine coronary artery endothelial cells were grown to confluence and incubated with palmitic acid. Palmitic acid induced rapid nuclear accumulation of heparanase that was dependent on Bax activation and lysosome permeabilization. Heat shock protein 90 was an important mediator of palmitic acid-induced shuttling of heparanase to the nucleus. Nuclear heparanase promoted cleavage of heparan sulfate, a potent inhibitor of histone acetyltransferase activity and gene transcription. A TaqMan gene expression assay revealed an increase in genes related to glucose metabolism and inflammation. In addition, glycolysis was uncoupled from glucose oxidation, resulting in accumulation of lactate.
H eparan sulfate proteoglycans are ubiquitous macromolecules present on cell membranes as part of the extracellular matrix, and consists of a core protein to which several linear heparan sulfate (HS) side chains are covalently linked. 1 They serve not only as structural proteins but also as receptors; HS can bind different proteins [growth factors, chemokines, cytokines, coagulation factors, and enzymes like LPL]. 2 This binding function provides the cell with a rapidly accessible reservoir, precluding the need for de novo synthesis when the requirement for a particular protein is increased. Recently, a unique function of HS in the nucleus has also been described, which includes the control of cell proliferation, shuttling of fibroblast growth factor 2, and inhibition of gene transcription. 3, 4 Heparanase, cloned in 1999, is an endoglycosidase that specifically cleaves carbohydrate chains of HS into oligosaccharides. 5 Human heparanase gene is located on chromosome 4q22, which encodes a polypeptide of 543 amino acids. It is first synthesized as a latent 65 kDa enzyme that undergoes secretion followed by reuptake into the cells. After undergoing proteolytic cleavage (primarily by cathepsin-L in lysosomes), a 50 kDa polypeptide is formed that is Ϸ200-fold more active than the 65 kDa type. 5, 6 Within the acidic compartment of the lysosome, active heparanase is stored in a stable form (half-life Ϸ30 hours) and can assist in the turnover of HS side chains. 7 Mobilization by demand can occur, where the enzyme is either secreted to degrade cell surface HS and release HS-bound proteins, or translocated to the nucleus to affect gene transcription. 6 Under normal physiological conditions, cellular energy is obtained via the oxidation of an assortment of different substrates including lactate, ketone bodies, glucose, and fatty acids (FA). In the heart, compared to glucose, fatty acid is the preferred substrate used by cardiomyocytes and contributes approximately 70% of the ATP necessary for normal contraction. 8 Vascular endothelial cells are quiescent and hence have a low energy demand compared to myocytes. In addition, these cells have a small number of mitochondria compared to metabolically active cells. 9 Thus, most of the energy obtained by endothelial cells is through glycolytic breakdown of glucose. 10 Hyperglycemia and hyperlipidemia are characteristic features associated with diabetes, and recently we reported a novel regulation of endothelial heparanase by these substrates. 11, 12 We described high glucose as a potent stimulator of endothelial heparanase secretion, which helps in the transfer of lipoprotein lipase from the cardiomyocyte to the vascular lumen, permitting augmented fatty acid provision to cardiomyocytes. Unlike high glucose, augmented concentrations of fatty acid increased the nuclear content of heparanase. In the current study, we examined the mechanism behind this nuclear translocation of heparanase in response to fatty acid and the consequences of this relocation. Our data suggest that fatty acids, by inducing lysosome permeabilization, initiates endothelial heparanase nuclear translocation and induction of gene transcription that affects glucose metabolism and inflammation.
Materials and Methods

Endothelial Cell Culture and Treatments
To examine the effect of fatty acid on endothelial heparanase, bovine coronary artery endothelial cells (bCAECs; Clonetics) were incubated with albumin-bound palmitic acid (PA; 0.5-1 mmol/L, molar ratio 1:6) at the indicated times. Twenty micromolar/liter of Bax channel blocker CN196810 (CN, Bax inhibitor) and 2 mol/L geldanamycin (GA; Hsp90 inhibitor) were used where indicated.
Isolation of Nuclear, Lysosome, and Mitochondrial Fractions
Nuclear, lysosome, and mitochondrial fractions were prepared as previously described. 13 
Western Blot and Immunoprecipitation
Western blot and immunoprecipitation were carried out as described previously. 11
Small Interfering RNA Transfection
Small interfering RNA (siRNA) was designed and synthesized by Applied Biosystems. Transfection was carried out using Lipofectamine TM 2000 reagent (Invitrogen) according to the manufacturer's instructions.
Histone Acetyltransferase Activity Assay
The histone acetyltransferase (HAT) activity of nuclear extracts was measured with a colorimetric HAT assay kit. This assay is based on the acetylation of substrate by active HAT released CoA, which serves to produce NADH that is detected by a tetrazolium dye.
Lactate Assay
Lactate was determined in the culture medium using a lactate assay kit.
Reverse Transcription-Quantitative Polymerase Chain Reaction
Total RNA was extracted using TRIzol (Invitrogen) and reverse transcription-quantitative polymerase chain reaction was performed using the TaqMan gene expression assay on a StepOnePlus system (Applied Biosystems) according to manufacturer's instructions.
Statistical Analysis
Values are meansϮSEM. Wherever appropriate, one-way ANOVA followed by the Tukey test was used to determine differences between groups mean values. The level of statistical significance was set at PϽ0.05. 
Results
Fatty Acid Stimulates Rapid Nuclear Accumulation of Heparanase
In endothelial cells, heparanase is located predominantly in the cytoplasm, with a small amount (Ϸ4%) present in the nucleus (Supplement Figure I , available online at http://atvb.ahajournals.org). To simulate hyperlipidemia, bCAECs were incubated with increasing concentrations of PA. PA concentration-dependently increased endothelial nuclear heparanase ( Figure 1A , inset). Using the 1 mmol/L concentration, cells were next treated for up to 30 minutes. PA time-dependently increased nuclear heparanase, with an approximately 2-fold augmentation of enzyme observed after 30 minutes ( Figure 1A ). With prolonged exposure to PA, the amount of nuclear heparanase dropped such that after 120 minutes, levels similar to 0 minutes were observed (data not shown). This nuclear increase was not reflected by a significant reduction in the cytoplasmic content of heparanase (Supplement Figure I ). In addition, this effect was not related to metabolism of PA, as 1 mmol/L 2-bromohexadecanoic acid (a nonmetabolizable palmitate analog) also had a similar effect ( Figure 1B) . Confirmation of the effect of PA on nuclear accumulation of heparanase was done using immunofluorescence. In endothelial cells, heparanase colocalized with lysosomes that had a predominant perinuclear distribution ( Figure 1C ). PA caused lysosomal heparanase escape and relocation into the nucleus ( Figure 1C , bottom panel). Overall, these experiments demonstrate that fatty acids possess an intrinsic ability to facilitate nuclear translocation of heparanase.
Nuclear Translocation of Heparanase is Dependent on Bax-Induced Lysosome Permeabilization
A prerequisite for nuclear entry of heparanase is likely lysosomal disruption with heparanase released into the cytoplasm. Bax activation has been suggested to induce lysosome permeabilization. 14 Incubation with PA or bromohexadecanoic acid significantly increased Bax activation, without changes in total Bax (Figure 2A ). Immunofluorescence images confirmed this observation, in addition to demonstrating colocalization of activated Bax with lysosomes ( Figure 2B ). Interestingly, the isolated lysosomal fraction from PA-treated cells exhibited lower heparanase and a higher content of activated Bax ( Figure 2C ). Cathepsin B (Ctsb), a lysosomal resident protease used as an indicator for lysosome integrity, was also decreased following PA in isolated lysosomes ( Figure 2C ). The PA-induced decrease in lysosomal Ctsb coincided with appearance of this lysosomal protease in the cytoplasm ( Figure 2D ). To further examine the effect of Bax Bovine coronary artery endothelial cells were treated with 1 mmol/L albumin-bound PA for 30 minutes, and activated (Bax 6A7) and total Bax determined in whole cell lysates (A). Cells were also stained with LysoTracker (green), anti-Bax mAb 6A7 (red), and anti-Ctsb (red) following 30 minutes incubation with PA (B and D). Barϭ20 m. Data are from a representative experiment done 3 times. Following isolation of lysosomes, heparanase, activated Bax, and Ctsb were also measured (C). LAMP-1 was used as a protein loading control (CON). Following pretreatment of bovine coronary artery endothelial cells with Bax inhibitor CN196810 (CN) (20 mol/L), cells were treated with 1 mmol/L PA for 30 minutes. Ctsb staining (D), nuclear heparanase (E), and activated Bax (E, inset) were determined. The representative Western blot and densitometric results illustrated are meanϮSEM for 3 experiments and are expressed as ratio to control. *Significantly different from control. #Significantly different from PA, PϽ0.05. BPA indicates bromohexadecanoic acid. activation on lysosome permeabilization, we used a Bax channel blocker CN. CN attenuated lysosomal loss of Ctsb ( Figure 2D , bottom panel). More importantly, CN prevented the nuclear translocation of heparanase in response to PA ( Figure 2E ). It should be noted that PA had no effect on caspase 3 activation (Supplemental Figure II) , suggesting that the increase in lysosomal permeability is not sufficient to trigger apoptosis up to 24 hours. Collectively, these data suggest that PA-induced nuclear translocation of heparanase is dependent on Bax activation and lysosome permeabilization.
Hsp90 Accompanies the Nuclear Translocation of Heparanase
In HL-60 leukemic cells, Hsp90 has been suggested to function as a chaperone for nuclear shuttling of heparanase. 15 Immunoprecipitation of cytosolic Hsp90 revealed a robust association between this chaperone and heparanase 15 minutes following PA, an association that tended to decrease with time ( Figure 3A) . Interestingly, the nuclear presence of Hsp90-bound heparanase following PA also increased after 15 minutes, with further amplification at 30 minutes ( Figure  3B ). As GA, a specific Hsp90 inhibitor, effectively blocked the nuclear entry of heparanase ( Figure 3C ), our data indicate that Hsp90 is an important mediator of PA-induced shuttling of heparanase to the nucleus.
Nuclear Heparanase is Associated With Cleavage of Heparan Sulfate
Heparanase is an endoglycosidase that can degrade heparan sulfate (HS) into small oligosaccharides. 5 Using immunostaining with anti-HS mAb 10E4, which targets intact HS chains, and anti-HS mAb 3G10, which detects cleaved HS chains, we examined the effect of PA on nuclear HS. 12, 16 With 10E4 staining, intact HS presented a cellular distribution that included both the cytoplasm and nucleus. Treatment with PA eliminated the presence of intact HS mainly in the nucleus ( Figure 4A ), an effect that was accompanied by the appearance of cleaved nuclear HS ( Figure 4B ). Quantification of this effect using Western blot demonstrated that the increase in cleaved nuclear HS was apparent at 30 minutes after PA, increased further with time, and remained high up to 4 hours ( Figure 4C ). Interestingly, similar to PA, bromohexadecanoic acid-induced nuclear translocation of heparanase was also associated with HS cleavage (data not shown). Blocking the nuclear entry of heparanase with GA reduced the amount of cleaved nuclear HS observed following PA ( Figure 4D ). These data suggest that nuclear HS can undergo cleavage following translocation of heparanase into the nucleus.
Heparanase Regulates HAT Activity and Genes Related to Glycolysis
Heparan sulfate is a potent inhibitor of HAT activity. 17 To determine if HAT activity changes following nuclear translocation of heparanase and HS cleavage, HAT activity in addition to acetylation of histone were evaluated. Using Western blot, we observed increased HAT activity and augmented histone acetylation after 60 minutes of PA ( Figure  5A ). These effects were attenuated by the Hsp90 inhibitor GA ( Figure 5B ). An expression assay for genes related to glycolysis revealed an increase in PDK2 and LDHA in endothelial cell treated with PA, effects that were prevented by GA ( Figure 5C ) or heparanase siRNA ( Supplemental Table I ). It should be noted that in addition to genes controlling glucose metabolism, nuclear entry of heparanase was also associated with an increase in genes related to inflammation, like VCAM1, SERPINE1 and VEGFA, effects that were prevented by GA (Supplemental Figure III) or heparanase siRNA ( Supplemental Table II ).
PDK2 Expression and Extracellular Lactate Accumulation Are Regulated by Nuclear Heparanase
PDK can reduce the oxidative breakdown of glucose through its inactivation of PDH. In response to 1 mmol/L PA, both PDK2 gene and protein increased as early as 6 hours, and remained high until 12 hours ( Figure 6A ). This effect occurred in the absence of activation peroxisome proliferatoractivated receptor-␣ (Supplemental Figure IV) . This increase fractions were isolated and subjected to immunoprecipitation using anti-Hsp90 antibody, and immunoblotted with antiheparanase mAb 130 and anti-Hsp90 antibody. Cells were also pretreated with geldanamycin (GA) (2 mol/L for 60 minutes) and then exposed to 1 mmol/L PA for 30 minutes. Nuclear heparanase was measured using Western blot (C). Results are meanϮSEM for 3 experiments and are expressed as ratio changes. *Significantly different from 0 minutes/control (CON). #Significantly different from PA, PϽ0.05.
in PDK2 was associated with augmented PDH phosphorylation ( Figure 6A , inset). Using siRNA, we were successful in reducing total endothelial heparanase ( Figure 6B , left panel). In these cells, PA-induced nuclear entry of heparanase and HS cleavage was reduced ( Figure 6B , right panel). More importantly, depletion of heparanase completely prevented the PA-induced increases in PDK2 gene and protein, as well as PDH phosphorylation ( Figure 6C ). Phosphorylation and inactivation of PDH uncouples glycolysis from glucose oxidation, resulting in accumulation of lactate. Measurement of lactate revealed a robust increase in the incubation medium following PA ( Figure 6D, inset) , an effect that was effectively prevented by GA or heparanase siRNA ( Figure 6D ). Our data clearly demonstrate an important role of nuclear heparanase on glucose metabolism through its effect on PDK2. It should be noted that compared to PDK2, although PA also increased PDK4 expression, this increase occurred at a later time of incubation (12 hours) (Supplemental Figure V) . We observed no change in PDK1 protein.
Discussion
Heparanase, an enzyme that has a predominant cytoplasmic localization, is present mainly in lysosomes. 7 However, in response to high fatty acid, a nuclear localization of this endoglycosidase has also been reported by us in endothelial cells. 11 Given the function of heparanase to cleave HS, and the impact that HS has on gene transcription, the present study focused on the mechanisms by which fatty acid induces nuclear translocation of heparanase. Our data demonstrates that PA triggers lysosome permeabilization, nuclear shuttling of released heparanase by Hsp90, and induction of genes that affect glucose metabolism and inflammation.
In endothelial cells exposed to PA, a rapid nuclear accumulation of heparanase was observed. This nuclear presence of heparanase is not uncommon, and several groups have detected this enzyme in the nucleus of MDA-435 human breast carcinoma cells and U87 glioma cells that were stable transfected with heparanase. 18 As the nonmetabolizable palmitate analog bromohexadecanoic acid had similar effects in mediating nuclear translocation of heparanase, it is unlikely that this nuclear shuttling requires prior oxidation of fatty acids. Given the immediate effect of fatty acids in translocating heparanase, we determined the cellular location of heparanase. Immunofluorescent images showed that heparanase was colocalized within lysosomes, in close proximity to the nucleus. This perinuclear position of heparanase precludes protracted transit time and could explain the quick nuclear entry of heparanase in response to fatty acids.
Given the predominant lysosome localization of heparanase, its prior release from lysosomes would be anticipated before its nuclear entry. In HepG2 cells, high fatty acidinduced lysosome permeabilization is preceded by activation of the proapoptotic protein Bax. 19 A Bax-dependent lysosome disruption is also involved in the ␣-lactalbumin and oleic acid-induced early leakage of lysosomes in tumor cells. 20 Results from this study also implicate Bax in the PA-induced nuclear entry of heparanase in endothelial cells. Thus, fatty acids induced Bax activation, which colocalized with lysosomes and was associated with release of lysosome contents including heparanase and Ctsb. At present, the mechanism by which fatty acid induces lysosomal permeabilization through Bax is unclear. In mitochondria from human cancer cells, activated Bax undergoes a conformational change, binds to the mitochondrial outer membrane to form complex oligomer pores, and induces membrane potential loss and permeabilization. 21 Interestingly, overexpression of Bcl-X L , which antagonizes Bax pore formation activity, prevented PA-induced lysosomal permeabilization in HepG2 cells. 22 As the Bax channel blocker CN also inhibited lysosomal leakiness in this study, our data provide strong evidence that PA-induced lysosomal permeabilization and release of heparanase is related to Bax induced pore formation.
Although different pathways exist for nuclear import of proteins, common shared features include a nuclear localization sequence, carrier molecules, and translocation through nuclear pore complexes. 23 Human heparanase contains 2 potential nuclear localization sequences (residues 271-277 and 427-430). 18 Regarding carriers, at least with the glucocorticoid receptor, a ubiquitous chaperone protein Hsp90, binds with the glucocorticoid receptor and together with the immunophilin assembly system, forms a transportosome to help glucocorticoid receptor shift from cytoplasm to nucleus. 24 Recently, a role for Hsp90 as a chaperone for nuclear translocation of heparanase has also been reported in HL-60 cells. 15 Consistent with this report, our immunoprecipitation experiments revealed a robust cytoplasmic association between Hsp90 and heparanase, and their time-dependent shuttling into the nucleus. As the Hsp90 inhibitor GA effectively abolished the nuclear presence of heparanase in response to PA, our study suggests that Hsp90 is the likely carrier in nuclear shuttling of heparanase in endothelial cells.
HS are linear polysaccharide chains that require vesicle transport to be transferred onto the cell surface. 1 However, the presence of HS in the nucleus has been reported in various cell types. 25, 26 For example, in primary hepatocytes, 18% of the total intracellular HS pool is located in the nucleus. 26 Our immunofluorescent images also demonstrated staining for intact HS in the nucleus of endothelial cells. With PA, staining for intact nuclear HS was lost, and this coincided with appearance of cleaved HS in the nucleus. It should be noted that although intact HS displayed whole cell distribution, cleaved HS following PA was only evident in the nucleus. One explanation for this observation is the possibility that released heparanase from lysosomes has limited access to intact HS that are transported in vesicles. As GA, which prevented the nuclear entry of heparanase, effectively attenuated the cleavage of nuclear HS, our data suggest that it is the PA-induced nuclear entry of heparanase that facilitates HS cleavage. The unique location of cleaved HS stimulated us to examine nuclear functions of HS. Recently, HS has been reported to be a potent repressor of gene transcription through its inhibitory effect on HAT, the enzyme that acetylates the lysine side chain of histone, allowing access of transcription factors to bind DNA and initiate transcription. 4, 17 Indeed, augmented HAT activity and histone acetylation were observed when nuclear HS was cleaved, effects that were prevented by GA. A broad range of genes are regulated by HAT, including genes related to cell metabolism and inflammation. 27 As our special interest was glucose metabolism that is a major provider of ATP to endothelial cells, we carried out a gene expression assay for key enzymes in this pathway. Interestingly, activation of gene expression was limited to genes encoding glucose oxidation (PDK2), and lactate formation (LDHA). As these effects were attenuated by GA or heparanase siRNA, our data suggest that PA can influence gene transcription through nuclear entry of heparanase.
Phosphorylation of the PDH complex at its E1 site by PDK has been recognized to inactivate PDH and lower glucose oxidation. 28 In response to starvation and diabetes, PDK expression is adjusted in a tissue-dependent manner; PDK expression increases in heart and skeletal muscle, but not in brain. 29 -31 Of the different isoforms of PDK, PDK2 is a ubiquitously and abundantly present isoenzyme. 32 As PDK2 responds rapidly to control the PDH complex, 32 we examined its endothelial expression following PA treatment. PA for 6 hours was sufficient to induce PDK2 mRNA and protein, with a corresponding increase in the phosphorylation of PDH. In skeletal muscle and heart, fatty acid is a well-known stimu- Figure 5 . Nuclear heparanase regulates histone acetyltransferase (HAT) activity and genes involved with glucose metabolism. Bovine coronary artery endothelial cells were treated with 1 mmol/L palmitic acid (PA) up to 4 hours, and nuclear fractions isolated at the indicated times to measure HAT activity and histone acetylation (A). This experiment was repeated in cells pretreated with 2 mol/L GA for 60 minutes, followed by incubation with 1 mmol/L PA for 60 minutes (B). In a different experiment, bovine coronary artery endothelial cells were incubated with 1 mmol/L PA up to 24 hours in the absence or presence of geldanamycin. RNA was isolated to analyze genes involved predominantly with glycolysis using a TaqMan gene expression assay (C). Data shown represents fold change relative to control (CON). The representative Western blot and densitometric results illustrated are meanϮSEM for 3 separate experiments. *Significantly different from control. #Significantly different from PA group, PϽ0.05.
lator of PDK through activation of peroxisome proliferator-activated receptor ␣. 33 As peroxisome proliferator-activated receptor␣ was unaffected by PA up to 24 hours, and as silencing of heparanase prevented these effects of PA on PDK2 and PDH, our study provides evidence for another potential regulator of PDK in endothelial cells. Inactivation of PDH uncouples glucose oxidation from glycolysis, resulting in increased pyruvate conversion to lactate as observed in this study. As this lactate accumulation was prevented by GA or heparanase siRNA, our present data also suggest a key role for nuclear heparanase in regulation of endothelial glucose metabolism.
Patients with diabetes are predisposed to developing atherosclerosis, and inflammation is considered an important regulatory process in early development of the atheromatous lesion. The critical role of VCAM1, plasminogen activator inhibitor type 1, and VEGFA in the development of atherosclerosis has been reported in different studies. 34 -36 VCAM is expressed on activated endothelial cells, and promotes monocyte and T lymphocyte adhesion and accumulation on the vessel wall. Plasminogen activator inhibitor type 1 is a major inhibitor preventing the process of fibrinolysis and VEGFA actively participates in atherogenesis through multiple mechanisms, including microvessel proliferation and monocyte infiltration. In our study, these inflammatory genes were upregulated following FA-induced nuclear translocation of heparanase. However, whether this effect contributes to the increased susceptibility of patients with diabetes to atherosclerosis requires further investigation.
In conclusion, the results presented in this study demonstrate that fatty acid can provoke lysosomal release of heparanase, its nuclear translocation, and activation of genes controlling glucose metabolism and inflammation. The ensuing uncoupling between glucose oxidation and glycolysis leads to accumulation of lactate. Given that lactate and its lowering of pH has been implicated in the progression of atherosclerosis through its promotion of lipoprotein binding to proteoglycans, 37 angiogenesis, and plaque rupture, 9, 38 and the critical role of VCAM, plasminogen activator inhibitor type 1, and VEGF in the development of atherosclerosis, 34, 35 these data detailing the novel mechanism by which FA shuttles endothelial heparanase into the nucleus may serve to reduce the associated cardiovascular complications seen during diabetes.
Limitations
When examining the effects of PA on the heart, most studies have used up to 1.2 mmol/L PA to duplicate the plasma concentration of total free FA observed with diabetes. 39, 40 In all of our Type 1 models of diabetes (streptozotocin or diazoxide), 41, 42 the plasma concentration of FA reaches 1 mmol/L. We acknowledge that not all of the FA measured in these diabetic models is PA, and that albumin-bound PA may only make up a fraction of the total plasma-free FA. Thus, the 1 mmol/L concentration of PA used in this study may be higher than the actual circulating amount bound to albumin. However, FA derived from the albumin-bound fraction does not account for all of the FA provided to the heart. Thus, other physiologically relevant sources like hydrolysis of lipoproteins by cardiac LPL, which has a selective affinity toward PA containing lipoproteins (47.5% of total FA released), 43 also play some role in the provision of PA. This Figure 6 . Nuclear heparanase increases PDK2 expression and extracellular lactate accumulation. Cells were treated with 1 mmol/L palmitic acid (PA) up to 12 hours. At the indicated times, mitochondrial fractions were isolated to detect PDK2 protein and phosphorylation of PDH (p-PDH) (A, inset). RNA was also isolated to identify PDK2 gene expression (A). Bovine coronary artery endothelial cells were transfected with heparanase amall interfering (siRNA) (B, left) . These cells were exposed to 1 mmol/L PA for 30 minutes and nuclear heparanase and cleaved heparan sulfate (HS) were detected (B, right) . The effect of heparanase siRNA on PA-induced PDK2 expression and p-PDH is illustrated in C. In a separate experiment, cells were treated with 1 mmol/L PA in the presence or absence of GA or heparanase siRNA for 24 hours, and medium collected to measure lactate (D, inset). Results are meanϮSEM for 3 separate experiments. *Significantly different from control (CON). #Significantly different from PA group, PϽ0.05.
is particularly important as 1) LPL increases in diabetic hearts, 2) the molar concentrations of FA in lipoproteins are approximately 10-fold higher than that of FA bound to albumin, and 3) circulating plasma triglyceride concentrations increase to 1.4 to 2 mmol/L after diazoxide and streptozotocin. 41, 42 As intracellular triglyceride and membrane phospholipids are also potential sources of PA, a true measure of the effects of PA on heparanase would only be possible if all of these sources of PA are determined. Finally, high concentrations of PA can induce cell toxicity. Indeed, at 1 mmol/L PA, a significant decrease (Ϸ30%) in the number of viable endothelial cells and increase (Ϸ35%) in the release of LDH was observed compared to cells in the absence of PA (Supplemental Figure IX) . Thus, it is possible that some of the effects of heparanase could be secondary to cell toxicity. Nevertheless, using 0.5 mmol/L PA (which did not significantly affect cytotoxicity) increased expression of genes related to glycolysis and inflammation ( Supplemental Table  III ) was also observed. Overall, our data suggests that the effect of heparanase, at least with lower concentrations of PA, is independent of cytotoxicity, whereas with 1 mmol/L PA, cytotoxicity may contribute toward its effect.
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